INDICATIONS AND USAGE（适应症）

Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

DOSAGE（服用剂量）

Carbidopa and levodopa extended-release tablets contain carbidopa and levodopa in a 1:4 ratio as either the 50-200 tablet or the 25-100 tablet. The daily dosage of carbidopa and levodopa extended-release tablets must be determined by careful titration. Patients should be monitored closely during the dose adjustment period, particularly with regard to appearance or worsening of involuntary movements, dyskinesias or nausea. Carbidopa and levodopa extended-release tablets should not be chewed or crushed.

Standard drugs for Parkinson’s disease, other than levodopa without a decarboxylase inhibitor, may be used concomitantly while carbidopa and levodopa extended-release tablets are being administered, although their dosage may have to be adjusted.

Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, carbidopa and levodopa extended-release tablets can be given to patients receiving supplemental pyridoxine (vitamin B 6).

ADVERSE REACTIONS（不良反应）

Dyskinesia

Nausea

Hallucinations

Confusion

Dizziness

Depression

Urinary tract infection

Headache

Dream abnormalities

Dystonia

Vomiting

Upper respiratory infection

Dyspnea

‘On-Off’ phenomena

Back pain

Dry mouth

Anorexia

Diarrhea

Insomnia

Orthostatic hypotension

Shoulder pain

Chest pain

Muscle cramps

Paresthesia

Urinary frequency

Dyspepsia

Constipation

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/16f9e4d1-6953-4d4f-b4cf-ad95a856ac25/spl-doc?hl=Carbidopa%20and%20Levodopa

Carbidopa and Levodopa CR Tabletsinformation